*Note, this publication refers to the legacy name of our technology, now branded and trademarked as Celletto™

Solopore™ is a new, better, nanomechanical cell transfection approach that outperforms the prevailing non-viral approaches (like electroporation) and mitigates the limitations of current viral (biological) approaches. The under two-minutes sophisticated and high-resolution medical animation video shows how SoloPore™ works, and why this technology will transform the engineering of cell-based therapies.

July 7, 2020 – Basilard BioTech, Inc., a Southern California-based biotech company formed in July, 2019 to commercialize – through an exclusive IP license (covering all fields of use) – their novel, disruptive nanomechanical gene delivery technology platform (the product of over a decade’s worth of R&D in the UC Riverside Lab of Dr. Masa Rao), now commercially known as SoloPore™, announce the premiere of their new HD animation video which showcases how SoloPore™ works, using sophisticated HD medical animation. The video is available through the following links: 

Direct to YouTube: https://www.youtube.com/watch?v=ufzS-rBUmrY&feature=youtu.be 

On a link from Basilard BioTech’s Company Page on LinkedIn https://www.linkedin.com/company/basilardbiotech/?viewAsMember=true 

On a link from Basilard BioTech’s new (under construction) website: https://basilardbiotech.com/

About SoloPore™

SoloPore™ addresses the current ex-vivo gene delivery bottlenecks in cell therapy by demonstrating: 1) the consistent achievement of higher transfection and cell viability performance and yields vs. the industry-leading bulk electroporation platform currently used widely, and 2) compared to viral delivery, greater scalability, safety, efficiency and versatility than prevailing viral delivery methods, as well as lower cost & lead time. SoloPore™ is a superior platform for primary T cell engineering than either electroporation or prevailing viral delivery methods.

SoloPore™’s key differentiators include: precision, single-site cellular poration (compared to many, random – and damaging – holes created by electrical charges or squeezing), consistent nuclear delivery (not demonstrable in current approaches), massive parallelization (to meet scalability to higher numbers of cells per cycle – a critical threshold for cell therapy companies), rapid cell processing (minimal cycle time – millions of cells in minutes), and simplified operation (driven by a single pump, no moving parts). It also allows for significant enhancements (add-ons) in future versions, including automation, enclosed systems, software and other value-added upgrades.

The new, commercial prototypes of SoloPore™ will be capable of cycling 250,000 cells/cycle (a 25x improvement over the original lab scale device), a threshold sufficient for early technology evaluation by prospective co-development partners. Future versions will be scalable up to 200 million cells/cycle. These prototypes are currently in development with the delivery of up to 40 commercial prototype SoloPore™ devices expected by the fall of 2020. These chips will be used for validation testing (internally and with external research institutions) and to gain traction with prospective commercial partners (cell therapy companies) under technology evaluation agreements, and eventually, co-development partnerships.

Basilard BioTech are currently engaged in a Series Seed Capital Raise round. For more information about Basilard BioTech, the development and commercialization of SoloPore™ or our fundraising, contact: Brynley Lee, CEO at: brynleylee@basilardbiotech.net.